View:
BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703
(919) 859-1302
May 12, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Courtney Lindsay and Celeste Murphy
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Courtney Lindsay and Celeste Murphy
| Re: |
BioCryst Pharmaceuticals, Inc.
|
Registration Statement on Form S-3 (File No. 333-237820)
Filed April 24, 2020
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, BioCryst Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company (the “Registration Statement”) be accelerated to 4:00 p.m., Eastern Daylight Time, on May 14, 2020 or as
soon thereafter as practicable.
[Signature page follows]
|
Very truly yours,
|
|
|
BioCryst Pharmaceuticals, Inc.
|
|
|
/s/ Alane Barnes
|
|
|
Alane Barnes
|
|
|
Senior Vice President and Chief Legal Officer
|
cc: Robyn Zolman, Gibson, Dunn & Crutcher LLP